Integrated Biopharma Inc (INBP) Return on Equity ROE from the fourth quarter 2026 to fourth quarter 2025 and annually, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Integrated Biopharma Inc  (INBP)

Integrated Biopharma Inc's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Integrated Biopharma Inc in the fourth quarter 2026?
Integrated Biopharma Inc recorded a cumulative net loss of $-3 million during 12 months ending in the fourth quarter 2026, resulting in a negative return on equity (ROE) of -14.68%.

Within the Major Pharmaceutical Preparations industry 84 other companies had a higher return on equity. While Return on equity, overall ranking has advanced in the quarter, so far to 2641, from total ROE ranking in the third quarter 2026 at 2751.

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Jun 30 2026)
IV. Quarter		 (Mar 31 2026)
III. Quarter		 (Dec 31 2025)
II. Quarter		 (Sep 30 2025)
I. Quarter		 (Jun 30 2025)
IV. Quarter
Y / Y Equity Change -13.04 % -6.87 % 5.61 % 10.45 % -
Y / Y Net Income Change - - - -52.51 % -
Net Income (TTM) in Millions -3 -2 0 1 1
Return On Equity (TTM) -14.68 % -8.26 % -1.01 % 3.34 % 4.12 %
INBP's Total Ranking # 2641 # 2751 # 2114 # 2039 # 1785
Equity (TTM) in Millions 18 19 20 20 20
Seq. Equity Change -6.93 % -6.57 % -0.84 % 0.85 % -0.32 %
Seq. Net Income Change - - - - -

Back to INBP Management Effectiveness >> INBP's 5 Years Annual ROE >> Compare INBP ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry # 85
Sector # 253
Overall # 2641

Return On Equity Statistics
High Average Low
171.24 %
39.65 %
-14.68 %
(Jun 30 2019)   (Jun 30 2026)





INBP Annual Return On Equity (Jun 30 2026)
2026		 (Jun 30 2025)
2025		 (Jun 30 2024)
2024		 (Jun 30 2023)
2023		 (Jun 30 2022)
2022
Total Equity in Millions 18 20 19 19 19
Y / Y Equity Change -13.04 % 5.61 % 2 % 1.54 % 29.59 %
Net Income in Millions -3 1 0 0 4
Y / Y Net Income Change - 621.43 % - - -52.1 %
Return On Equity -16.09 % 3.98 % 0.58 % -0.18 % 20.66 %

Back to INBP Management Effectiveness >> INBP's 5 Years Annual ROE >> Compare INBP ROE to its Competitors




More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
INBP's' Return on Equity at Yahoo Finance
INBP's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for INBP's Competitors
Subscribers only: Roe for Integrated Biopharma Inc's Suppliers
Subscribers only: Return On Equity for INBP's Customers




Companies with similar Return On Equity at Jun 30 2026, within Healthcare Sector ROE

Date modified: 2026-09-27T08:12:16+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.